Neural Noise

40 Hz sensory stimulation and long-term benefit in Alzheimer's disease

2 min read

  • 40 Hz sensory stimulation is a neuromodulation approach with neural dynamics (gamma) relevance.1
  • Five volunteers received 40 Hz stimulation for around two years after an early-stage clinical study.1
  • Participants with late-onset Alzheimer’s performed better on assessments than Alzheimer’s patients outside the trial.1
  • The result supports long-term feasibility and a possible late-onset subgroup benefit (MIT News, Nov 2025).1 1

Weekly enrichment (2026-07-20)

  • The open-label extension (MIT News, 14 Nov 2025; published in Alzheimer’s & Dementia) followed 5 volunteers who continued daily 40 Hz light-and-sound GENUS stimulation for about two years after MIT’s early-stage clinical trial, the longest-term test of the noninvasive method to date.1
  • The 3 late-onset AD participants (all female) scored significantly higher than age/sex/cognition-matched controls drawn from national databases on 3 cognitive tests, and showed increased brain-wave responsiveness and improved circadian-rhythm measures at 30 months.1
  • In the 2 late-onset volunteers who provided plasma, phosphorylated tau (pTau217) fell 47% and 19.4% on a test recently approved by the FDA as the first plasma biomarker for diagnosing Alzheimer’s.1
  • The 2 early-onset male participants showed no significant cognitive benefit and significantly reduced brain-wave responsiveness, leading the authors to attribute the differential response to disease onset rather than gender.1
  • The original 2020 MIT trial enrolled 15 mild-AD volunteers for one hour/day of 40 Hz stimulation delivered via an in-home LED panel and speaker; though cut short by Covid-19, it found significant benefits at three months (preserved brain volume was not significant at the 30-month point).1
  • The approach is being scaled by MIT spinoff Cognito Therapeutics, whose pivotal Phase 3 HOPE trial (NCT05637801) is the largest AD-focused medical-device pivotal trial, enrolling ~670 mild-to-moderate AD patients at 70 U.S. sites for 60 min/day of Spectris AD stimulation over 12 months, with primary completion estimated June 2026.2 3
  • Cognito’s earlier OVERTURE study reported a 76% reduction in cognitive decline (MMSE), a 77% reduction in functional decline (ADCS-ADL), and roughly a 69% reduction in whole-brain atrophy over 6 months.3
  • GENUS (gamma entrainment using sensory stimuli) is designed to entrain 40 Hz gamma to target amyloid, tau, and neuroinflammation; it holds FDA Phase 3 status for Alzheimer’s and is also being explored in Parkinson’s disease and Down syndrome.4

Footnotes

  1. https://news.mit.edu/2025/study-suggests-40hz-sensory-stimulation-may-benefit-some-alzheimers-patients-1114 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  2. https://clinicaltrials.gov/study/NCT05637801 ↩

  3. https://www.biospace.com/press-releases/cognito-therapeutics-completes-enrollment-in-hope-pivotal-study-of-spectris-ad-therapy-for-the-treatment-of-patients-with-alzheimers-disease ↩ ↩2

  4. https://www.alzforum.org/therapeutics/sensory-stimulation-systems ↩

Graph View